高级检索
当前位置: 首页 > 详情页

Tangshen Formula Improves Diabetes-Associated Myocardial Fibrosis by Inhibiting TGF-beta/Smads and Wnt/beta-Catenin Pathways

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China, [2]National Energy R&D Center for Biorefinery, Beijing University of Chemical Technology, Beijing, China, [3]College of Pharmacy, Weifang Medical University, Weifang, China
出处:
ISSN:

关键词: Tangshen Formula myocardial fibrosis TGF- beta /Smad Wnt/ -catenin KKAy

摘要:
Cardiovascular disease has become the main cause of death among complications of diabetes. Myocardial fibrosis is a crucial pathological change of cardiovascular disease. Tangshen Formula (TSF) shows a good clinical effect in the treatment of diabetic kidney disease (DKD). However, whether TSF alleviates diabetes-associated myocardial fibrosis is still unknown. In the present research, we studied the effect and mechanism of TSF in the treatment of myocardial fibrosis in vivo and in vitro. We found that TSF treatment significantly downregulates myocardial fibrosis-related markers, including collagens I and III, and alpha-SMA. TSF also protects primary mouse cardiac fibroblast (CF) from transforming growth factor-beta 1- (TGF-beta 1-) induced damage. Moreover, TSF decreased the expression levels of TGF-beta/Smad-related genes (alpha-SMA, collagens I and III, TGF-beta 1, and pSmad2/3), and increased Smad7 gene expression. Finally, TSF decreased the expressions of wnt1, active-beta-catenin, FN, and MMP7 to regulate the Wnt/beta-catenin pathway. Taken together, TSF seems to attenuate myocardial fibrosis in KKAy mice by inhibiting TGF-beta/Smad2/3 and Wnt/beta-catenin signaling pathways.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
JCR分区:
出版当年[2019]版:
Q1 MEDICINE, GENERAL & INTERNAL
最新[2024]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2024版] 最新五年平均[2021-2025] 出版当年[2019版] 出版当年五年平均[2015-2019] 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China, [2]National Energy R&D Center for Biorefinery, Beijing University of Chemical Technology, Beijing, China,
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:819 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)